Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CGTX

CGTX - Cognition Therapeutics, Inc. Stock Price, Fair Value and News

$1.24-0.08 (-6.06%)
Market Closed

15/100

CGTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

15/100

CGTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.14

Target 3M

$1.29

Target 6M

$1.22

CGTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CGTX Price Action

Last 7 days

-12.7%

Last 30 days

-12.1%

Last 90 days

-24.8%

Trailing 12 Months

63.2%

CGTX RSI Chart

CGTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CGTX Valuation

Market Cap

109.5M

Price/Earnings (Trailing)

-3.91

Price/Sales (Trailing)

6.18

EV/EBITDA

-5.27

Price/Free Cashflow

-3.71

CGTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.14

Target 3M

$1.29

Target 6M

$1.22

CGTX Fundamentals

CGTX Revenue

Revenue (TTM)

17.7M

Rev. Growth (Yr)

-71.7%

Rev. Growth (Qtr)

-82.9%

CGTX Earnings

Earnings (TTM)

-28.0M

Earnings Growth (Yr)

50.39%

Earnings Growth (Qtr)

26.79%

CGTX Profitability

EBT Margin

-115.75%

Return on Equity

-76.61%

Return on Assets

-64.49%

Free Cashflow Yield

-26.98%

CGTX Investor Care

Shares Dilution (1Y)

112.46%

Diluted EPS (TTM)

-0.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202521.6M23.8M17.7M0
202426.3M26.7M23.3M0
202319.7M20.3M22.0M24.8M
202218.7M20.4M23.3M22.2M
202112.5M14.2M15.8M17.4M
202000010.9M
Get all data in R, Python etc through our Historical Stock Data APIs

About Cognition Therapeutics, Inc.

CGTX
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.
 CEO
 WEBSITEcogrx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES22

Cognition Therapeutics, Inc. Frequently Asked Questions

CGTX is the stock ticker symbol of Cognition Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Cognition Therapeutics, Inc. is 109.46 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CGTX's fair value in chart for subscribers.

The fair value guage provides a quick view whether CGTX is over valued or under valued. Whether Cognition Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Cognition Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CGTX.

As of Wed Jan 28 2026, CGTX's PE ratio (Price to Earnings) is -3.91 and Price to Sales (PS) ratio is 6.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CGTX PE ratio will change depending on the future growth rate expectations of investors.